Tetrakis(hydroxymethyl)phosphonium chloride

Repeated dose toxicity: oral

Administrative data

Endpoint:

sub-chronic toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Published test report from National Toxicology Program (US). Evaluated data from a reliable secondary source (US-CPSC).

Data source

Reference

Reference 1

Reference Type:

publication

Title:

Unnamed

Year:

1987

Report date:

1987

Reference 2

Reference Type:

secondary source

Title:

Unnamed

Year:

1999

Report date:

1999

Materials and methods

Principles of method if other than guideline:

13 week agavage study in rats.

GLP compliance:

not specified

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Tetrakis(hydroxymethyl)phosphonium chloride

EC Number:

204-707-7

EC Name:

Tetrakis(hydroxymethyl)phosphonium chloride

Cas Number:

124-64-1

Molecular formula:

C4H12O4P.Cl

IUPAC Name:

tetrakis(hydroxymethyl)phosphonium chloride

Details on test material:

80% (nominal) aqueous solution of THPC.

Test animals

Species:

rat

Strain:

Fischer 344

Sex:

male/female

Details on test animals or test system and environmental conditions:

Animals were housed five per cage. Feed and water were avaliable ad libitum.

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

water

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

The same method was used to analyze THPC doses in water at both the analytical chemistry (100% and 80% level) and the study laboratories ( 36-1 mg/mL). It involved oxidation of the cation of THPC with potassium iodate and back-titration with sodium thiosulfate (Frank, 1977).

Duration of treatment / exposure:

5 days/week for 13 weeks

Frequency of treatment:

once per day (Mo-Fr)

Doses / concentrations

Remarks:

Doses / Concentrations:
0, 3.75, 7.5, 15, 30 or 60 mg/kg bw/day
Basis:
actual ingested

No. of animals per sex per dose:

10

Control animals:

yes, concurrent vehicle

Details on study design:

2 observations per day
weighed once per week

Examinations

Sacrifice and pathology:

Necropsy performed on all animals; histologic examinations performed on the following tissues from all rats that died before end of
studies in the vehicle control, 30 mg/kg. and 60 mg/kg groups. and from 2 rats/sex in 15 mg/kg group; from all mice that died before end
ofstudies. from vehicle control.4S mg/kg, and 135 mg/kg groups. and from 2 mice/sex in 15 mg/kg group: skin, mandibular
lymph node, mammary gland, salivary gland, skeletal muscle, sciatic nerve, bone marrow, thymus, trachea, lungs and bronchi, heart,
thyroid gland, parathyroids, esophagus, stomach, small intestine, large intestine, mesenteric lymph node, iver, pancreas, spleen, kidneys,
adrenal glands. urinary bladder, prostate, testis or ovaries/uterus, brain, pituitary gland, spinal cord.
Liver, stomach, and skeletal muscle examined from all rats in 3.75, 7.5, and 15 mg/kg groups and kidneys from female rats in 3.75, 7.5, and 15
mg/kg groups.

Results and discussion

Results of examinations

Clinical signs:

effects observed, treatment-related

Mortality:

mortality observed, treatment-related

Body weight and weight changes:

effects observed, treatment-related

Food consumption and compound intake (if feeding study):

not examined

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

not examined

Haematological findings:

not examined

Clinical biochemistry findings:

not examined

Urinalysis findings:

not examined

Behaviour (functional findings):

not examined

Organ weight findings including organ / body weight ratios:

not examined

Gross pathological findings:

effects observed, treatment-related

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Histopathological findings: neoplastic:

not examined

Details on results:

All males and 5/10 females that received 60 mg/kg THPC and 2/10 males and 1/10 females that received 15 mg/kg died before the end of the studies (Table 10). Deaths in the 15 mg/kg groups may have been due to gavage error.
The final mean body weight of males that received 30 mg/kg was 89% that of the vehicle controls. The final mean body weight of females that received 60 mg/kg was 80% that of the vehicle controls.
Rough coats, hunched backs, diarrhea, lethargy, and paresis and hyperextension of the rear limbs were observed for rats that received 60 mg/kg.

Periportal hepatocellular necrosis was observed in 9/10 males and 7/10 females that received 15 mg/kg, 10/10 males and 10/10 females that received 30 mg/kg, and 7/10 males and 8/10 females that received 60 mg/kg. (The severity at 15 mg/kg was minimal.)
Periportal cytoplasmic vacuolization was observed in 8/10 males that received 7.5 mg/kg, 9/10 males and 8/10 females that received 15 mg/kg, and all rats that received 30 or 60 mg/kg.
Degeneration of the axons was found in 2/10 females that received 60 mg/kg but not in any of the rats that received 30 mg/kg.

Effect levels

1

Dose descriptor:

NOAEL

Effect level:

> 7.5 mg/kg bw/day (actual dose received)

Based on:

act. ingr.

Sex:

male/female

Basis for effect level:

other: Periportal hepatocellular necrosis at 15 mg/kg/day

2

Dose descriptor:

NOAEL

Effect level:

> 3.75 - < 7.5 mg/kg bw/day (actual dose received)

Based on:

act. ingr.

Sex:

male

Basis for effect level:

other: Periportal cytoplasmic vacuolization in males at 7.5 mg/kg/day

Target system / organ toxicity

Critical effects observed:

not specified

Applicant's summary and conclusion

Executive summary:

When rats received 0, 3.75, 7.5, 15, 30, or 60 mg/kg THPC by gavage for 13 weeks, treatment-related death occurred at 60 mg/kg

in both sexes (NTP 1987). Periportal hepatocellular necrosis was observed beginning at 15 mg/kg THPC and periportal cytoplasmic

vacuolization was observed in males beginning at 7.5 mg/kg THPC (NTP 1987).

For each sex the maximal tolerated dose was set at 7.5 mg/kg bw/day, to be used in the consecutive chonic study.